Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.08.2022 | Case report

Atezolizumab/gefitinib/osimertinib

Acquired resistance and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sueoka-Aragane N, et al. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Medicine 10: 3873-3885, No. 12, Jun 2021. Available from: URL: http://doi.org/10.1002/cam4.3929 Sueoka-Aragane N, et al. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Medicine 10: 3873-3885, No. 12, Jun 2021. Available from: URL: http://​doi.​org/​10.​1002/​cam4.​3929
Metadaten
Titel
Atezolizumab/gefitinib/osimertinib
Acquired resistance and lack of efficacy: case report
Publikationsdatum
01.08.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-21626-5

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Rituximab

Case report

Clobetasol

Case report

Multiple drugs